Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Jan 27;64(8):1150–1157. doi: 10.1136/ard.2004.032268

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

C Antoni 1, G Krueger 1, K de Vlam 1, C Birbara 1, A Beutler 1, C Guzzo 1, B Zhou 1, L Dooley 1, A Kavanaugh 1, t for 1
PMCID: PMC1755609  PMID: 15677701

Abstract

Objectives: To evaluate further in a phase III, double blind trial the efficacy of infliximab in patients with active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial.

Methods: 200 patients with active PsA unresponsive to previous treatment were randomised to infusions of infliximab 5 mg/kg or placebo at weeks 0, 2, 6, 14, and 22. Patients with inadequate response entered early escape at week 16. The primary measure of clinical response was ACR20. Other measures included Psoriatic Arthritis Response Criteria (PsARC), Psoriasis Area and Severity Index (PASI), and dactylitis and enthesopathy assessments.

Results: At week 14, 58% of patients receiving infliximab and 11% of those receiving placebo achieved an ACR20 response and 77% of infliximab patients and 27% of placebo patients achieved PsARC (both p<0.001). Among the 85% of patients with at least 3% body surface area psoriasis involvement at baseline, 53/83 (64%) patients receiving infliximab had at least 75% improvement in PASI compared with 2/87 (2%) patients receiving placebo at week 14 (p<0.001). These therapeutic effects were maintained through the last evaluation (week 24). Fewer infliximab patients than placebo patients had dactylitis at week 14 (18% v 30%; p = 0.025) and week 24 (12% v 34%; p<0.001). Fewer infliximab patients (22%) than placebo patients (34%) had active enthesopathy at week 14 (p = 0.016); corresponding figures at week 24 were 20% and 37% (p = 0.002). Infliximab was generally well tolerated, with a similar incidence of adverse events in each group.

Conclusions: Infliximab 5 mg/kg through 24 weeks significantly improved active PsA, including dactylitis and enthesopathy, and associated psoriasis.

Full Text

The Full Text of this article is available as a PDF (96.8 KB).

Figure 1.

Figure 1

Open in a new tab

 Summary of patient disposition, including the number of patients who were randomised to each treatment, entered early escape, discontinued treatment, and/or completed the study, in a controlled trial of infliximab and placebo in patients with PsA. *Three patients in the placebo group received infliximab at the first infusion in error and were not included in the safety analysis in the placebo group; †patients who discontinued treatment remained in the study and returned for evaluations; ‡all patients who discontinued the study are counted in the total patients who discontinued treatment.

Figure 2.

Figure 2

Open in a new tab

 Time pattern of arthritis response, as measured by various degrees of American College of Rheumatology (ACR) response in patients with PsA treated with infliximab or placebo.

Figure 3.

Figure 3

Open in a new tab

 Skin response over time, as measured by various degrees of the PASI improvement in patients with PsA treated with infliximab or placebo.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoni Christian E., Kavanaugh Arthur, Kirkham Bruce, Tutuncu Zuhre, Burmester Gerd R., Schneider Udo, Furst Daniel E., Molitor Jerry, Keystone Edward, Gladman Dafna. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005 Apr;52(4):1227–1236. doi: 10.1002/art.20967. [DOI] [PubMed] [Google Scholar]
  2. Antoni Christian, Dechant Claudia, Hanns-Martin Lorenz P. D., Wendler Joerg, Ogilvie Alexandra, Lueftl Mathias, Kalden-Nemeth Dolores, Kalden Joachim R., Manger Bernhard. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002 Oct 15;47(5):506–512. doi: 10.1002/art.10671. [DOI] [PubMed] [Google Scholar]
  3. Biondi Oriente C., Scarpa R., Pucino A., Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) 1989;146:69–71. [PubMed] [Google Scholar]
  4. Chaudhari U., Romano P., Mulcahy L. D., Dooley L. T., Baker D. G., Gottlieb A. B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001 Jun 9;357(9271):1842–1847. doi: 10.1016/s0140-6736(00)04954-0. [DOI] [PubMed] [Google Scholar]
  5. Clegg D. O., Reda D. J., Mejias E., Cannon G. W., Weisman M. H., Taylor T., Budiman-Mak E., Blackburn W. D., Vasey F. B., Mahowald M. L. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec;39(12):2013–2020. doi: 10.1002/art.1780391210. [DOI] [PubMed] [Google Scholar]
  6. Crowe W., Kushner I. An immunofluorescent method using Crithidia luciliae to detect antibodies to double-stranded DNA. Arthritis Rheum. 1977 Apr;20(3):811–814. doi: 10.1002/art.1780200308. [DOI] [PubMed] [Google Scholar]
  7. Danning C. L., Illei G. G., Hitchon C., Greer M. R., Boumpas D. T., McInnes I. B. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000 Jun;43(6):1244–1256. doi: 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  8. Feletar M., Brockbank J. E., Schentag C. T., Lapp V., Gladman D. D. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis. 2004 Feb;63(2):156–161. doi: 10.1136/ard.2003.006775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Felson D. T., Anderson J. J., Boers M., Bombardier C., Furst D., Goldsmith C., Katz L. M., Lightfoot R., Jr, Paulus H., Strand V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727–735. doi: 10.1002/art.1780380602. [DOI] [PubMed] [Google Scholar]
  10. Fredriksson T., Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. doi: 10.1159/000250839. [DOI] [PubMed] [Google Scholar]
  11. Gladman D. D., Farewell V. T., Wong K., Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998 Jun;41(6):1103–1110. doi: 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  12. Green L., Meyers O. L., Gordon W., Briggs B. Arthritis in psoriasis. Ann Rheum Dis. 1981 Aug;40(4):366–369. doi: 10.1136/ard.40.4.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hanauer Stephen B., Feagan Brian G., Lichtenstein Gary R., Mayer Lloyd F., Schreiber S., Colombel Jean Frederic, Rachmilewitz Daniel, Wolf Douglas C., Olson Allan, Bao Weihang. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541–1549. doi: 10.1016/S0140-6736(02)08512-4. [DOI] [PubMed] [Google Scholar]
  14. Husted J. A., Gladman D. D., Farewell V. T., Cook R. J. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001 Apr;45(2):151–158. doi: 10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  15. Kaltwasser J. Peter, Nash Peter, Gladman Dafna, Rosen Cheryl F., Behrens Frank, Jones Peter, Wollenhaupt Jürgen, Falk Franziska G., Mease Philip, Treatment of Psoriatic Arthritis Study Group Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004 Jun;50(6):1939–1950. doi: 10.1002/art.20253. [DOI] [PubMed] [Google Scholar]
  16. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996 Jul;14(3):485–496. doi: 10.1016/s0733-8635(05)70376-4. [DOI] [PubMed] [Google Scholar]
  17. Kruithof E., Van den Bosch F., Baeten D., Herssens A., De Keyser F., Mielants H., Veys E. M. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis. 2002 Mar;61(3):207–212. doi: 10.1136/ard.61.3.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  19. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  20. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  21. Mease Philip J., Kivitz Alan J., Burch Francis X., Siegel Evan L., Cohen Stanley B., Ory Peter, Salonen David, Rubenstein Joel, Sharp John T., Tsuji Wayne. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264–2272. doi: 10.1002/art.20335. [DOI] [PubMed] [Google Scholar]
  22. Ogilvie A. L., Antoni C., Dechant C., Manger B., Kalden J. R., Schuler G., Lüftl M. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001 Mar;144(3):587–589. doi: 10.1046/j.1365-2133.2001.04089.x. [DOI] [PubMed] [Google Scholar]
  23. Partsch G., Steiner G., Leeb B. F., Dunky A., Bröll H., Smolen J. S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997 Mar;24(3):518–523. [PubMed] [Google Scholar]
  24. Rapp S. R., Feldman S. R., Exum M. L., Fleischer A. B., Jr, Reboussin D. M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401–407. doi: 10.1016/s0190-9622(99)70112-x. [DOI] [PubMed] [Google Scholar]
  25. Salvarani Carlo, Cantini Fabrizio, Olivieri Ignazio, Macchioni Pierluigi, Padula Angela, Niccoli Laura, Catanoso Maria Grazia, Scocco Giovanni Lo, Boiardi Luigi. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. 2003 Aug 15;49(4):541–545. doi: 10.1002/art.11201. [DOI] [PubMed] [Google Scholar]
  26. Shbeeb M., Uramoto K. M., Gibson L. E., O'Fallon W. M., Gabriel S. E. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000 May;27(5):1247–1250. [PubMed] [Google Scholar]
  27. Sokoll K. B., Helliwell P. S. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001 Aug;28(8):1842–1846. [PubMed] [Google Scholar]
  28. Torre Alonso J. C., Rodriguez Perez A., Arribas Castrillo J. M., Ballina Garcia J., Riestra Noriega J. L., Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991 Aug;30(4):245–250. doi: 10.1093/rheumatology/30.4.245. [DOI] [PubMed] [Google Scholar]
  29. Van den Bosch F., Kruithof E., Baeten D., De Keyser F., Mielants H., Veys E. M. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428–433. doi: 10.1136/ard.59.6.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Whiting-O'Keefe Q. E., Fye K. H., Sack K. D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991 Jun;90(6):711–716. [PubMed] [Google Scholar]
  31. Wold R. T., Young F. E., Tan E. M., Farr R. S. Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid. Science. 1968 Aug 23;161(3843):806–807. doi: 10.1126/science.161.3843.806. [DOI] [PubMed] [Google Scholar]
  32. Wong K., Gladman D. D., Husted J., Long J. A., Farewell V. T. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997 Oct;40(10):1868–1872. doi: 10.1002/art.1780401021. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Italian translation]
annrheumd_ard.2004.032268_index.html (980B, html)
annrheumd_ard.2004.032268_1.pdf (494.4KB, pdf)

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES